http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Bionik Laboratories Reports Second Quarter Fiscal Year 2023 Financial Results
-
Bionik Laboratories to Present at the Q4 Virtual Investor Summit
-
Bionik Laboratories Appoints Richard Russo, Jr. as Chief Executive Officer and Dan Gonsalves as Chief Financial Officer
-
Bionik Laboratories Acquires Florida Rehabilitation Center; First in Strategic National Rollout
-
BIONIK Laboratories Reports First Quarter Financial Results
-
BIONIK Laboratories Corp. to Present at Investor Summit Group’s Q3 Virtual Conference
-
BIONIK Laboratories Announces the Sale & Installation of a New InMotion® ARM/HAND Robotic Device to Tampa General Hospital for its Rehabilitation Center
-
BIONIK Laboratories Reports Fourth Quarter and Fiscal Year 2022 Financial Results
-
BIONIK Laboratories to Attend the 2022 American Occupational Therapy Association (AOTA) Conference & Expo
-
BIONIK Laboratories Reports 15-20% Increase in Therapeutic Gains on InMotion® Robotic Devices in New Patient Outcomes Data Report
-
BIONIK Laboratories Reports Third Quarter Fiscal Year 2022 Financial Results
-
BIONIK Laboratories to Participate at the American Physical Therapy Association Conference
-
BIONIK Laboratories to Participate at MEDICA, a Leading International Trade Show for the Medical Industry
-
BIONIK Laboratories Reports Second Quarter Fiscal Year 2022 Financial Results
-
BIONIK Laboratories Announces Commercial Team Addition With Newly Hired Regional Sales Director, Tony Bellofatto
-
BIONIK Laboratories Reports a 72% Increase in Patient Sessions on its InMotion® Robotic Devices Since Launch of InMotion Connect™ Platform
-
BIONIK Laboratories Reports Fiscal 2022 Q1 Financial Results
-
BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes
-
BIONIK Laboratories Announces Resignation of CEO, Names Interim CEO
-
BIONIK Laboratories Reports Fiscal 2021 Financial Results
-
BIONIK Laboratories Reports Fiscal 2021 Q3 Financial Results
-
BIONIK Laboratories Corp. Appoints Rich Russo, Jr. as CFO
-
BIONIK Laboratories Announces Fiscal 2021 Q2 Financial Results
-
BIONIK Laboratories Announces Sale of New InMotion® ARM/HAND Robotic Device to VA Rehabilitation Research & Development’s Center for Neurorestoration and Neurotechnology
-
BIONIK Laboratories Announces Fiscal 2021 Q1 Financial Results
-
BIONIK Laboratories Announces Fiscal 2020 Financial Results
-
BIONIK Laboratories Launches InMotion Connect™, Driving Outcomes through Internet of Things (IoT) and Intelligent Data
-
BIONIK Laboratories Donates InMotion® Robotic System to Einstein Healthcare Network’s MossRehab for Use in New COVID-19 Rehab Unit
-
BIONIK Laboratories Announces Third Quarter Fiscal 2020 Financial Results
-
BIONIK Laboratories Announces Regulatory Approval and First Sale of its InMotion® ARM Robotic Technology by its Exclusive Distributor in South Korea
-
BIONIK Laboratories Selects Propel to Accelerate New Product Development and Manufacturing of InMotion Robotic Systems and Services
-
BIONIK Laboratories Announces Second Quarter Fiscal 2020 Financial Results
-
BIONIK Laboratories Partners with Intelliware Development to Provide Seamless Connectivity Between InMotionTM Robotic Devices and Hospital Information Systems
-
BIONIK Laboratories Appoints Loren Wass as Chief Commercial Officer
-
BIONIK Laboratories’ Fiscal Year 2020 Q1 Financial Results Feature 57% Increase in Sales
-
BIONIK Laboratories’ Fiscal 2019 Financial Results Feature 229% Increase in Sales
-
Landmark RATULS Research Trial of Robot-Assisted Stroke Therapy Utilizes BIONIK’s InMotion Robotic Therapy Systems
-
BIONIK Laboratories Third Quarter Fiscal 2019 Financial Results Feature 256% Increase in Sales
-
BIONIK Laboratories Launches Next-Generation InMotion ARM/HAND Robotic System to Improve Rehabilitation for Stroke Survivors
-
BIONIK Laboratories Announces Multi-Year Purchase Agreement and Ongoing Relationship with Kindred Hospital Rehabilitation Services for InMotion Arm™ Robotic Systems
-
Bionik Laboratories Files Registration Statement for Proposed Follow-On Offering
-
Bionik Laboratories Announces 1-for-150 Reverse Stock Split
-
BIONIK Laboratories Announces Purchase Agreement from Clinique Les Trois Soleils for InMotion Arm™ Robotic System
-
Bionik Laboratories Appoints Dr. Audrey D. Thévenon and Charles Matine to its Board of Directors
-
Bionik Laboratories Reports First Quarter Fiscal 2019 Financial Results
-
Bionik Laboratories Reports Fiscal Year 2018 Financial Results
-
Bionik Laboratories Announces Agreement with The Transitional Learning Center for InMotion Arm Robotic Systems
-
Bionik Laboratories Appoints Renaud Maloberti as Chief Commercial Officer
-
Bionik Laboratories Announces Rental Agreement with Tallahassee Memorial HealthCare for InMotion Arm Robotic System
-
Bionik Laboratories Issues Letter to Stockholders

